Ramucirumab og trifluridin/tipiracil eller paclitaxel til behandling af patienter med tidligere behandlet avanceret mave- eller gastroøsofageal kræft.
Ramucirumab Plus Trifluridin/Tipiracil (TAS-102) til patienter med tidligere behandlet avanceret gastrisk eller gastroøsofagealt adenokarcinom: Et investigator-initieret, randomiseret non-inferiority fase 2-studie
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stopping cell division which may kill tumor cells. Giving ramucirumab and trifluridine/tipiracil will not be worse than ramucirumab and paclitaxel in treating gastric or gastroesophageal junction cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Klinisk fase III gastrisk cancer AJCC v8
- Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Klinisk fase IV gastrisk cancer AJCC v8
- Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Metastatisk gastrisk adenocarcinom
- Metastatisk Gastroøsofageal Junction Adenocarcinoma
- Postneoadjuverende terapi Stage III Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi trin IIIA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stadium IIIB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stage IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stage IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stadium IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Klinisk fase IVA gastrisk cancer AJCC v8
- Klinisk fase IVB gastrisk kræft AJCC v8
- Patologisk fase III mavekræft AJCC v8
- Patologisk fase IIIA mavekræft AJCC v8
- Patologisk fase IIIB mavekræft AJCC v8
- Patologisk stadium IIIC mavekræft AJCC v8
- Patologisk fase IV mavekræft AJCC v8
- Klinisk fase IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Postneoadjuverende terapi Stage III gastrisk cancer AJCC v8
- Postneoadjuverende terapi Stage IV gastrisk cancer AJCC v8
- Klinisk fase IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk trin IIIA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk trin IIIB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk Stage IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Patologisk stadium IVB Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Lokalt avanceret uoperabelt gastrisk adenokarcinom
- Lokalt avanceret uoperabelt gastroøsofagealt adenokarcinom
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To compare, in a non-inferiority fashion, the progression-free survival (PFS) in patients with metastatic refractory gastric/gastroesophageal junction (GEJ) adenocarcinoma receiving the combination of ramucirumab with trifluridine and tipiracil hydrochloride (TAS-102) versus (vs.) paclitaxel and ramucirumab.
SECONDARY OBJECTIVES:
I. To assess overall survival (OS) in this patient population for each regimen. II. Assess changes in patient quality of life (QOL) as measured by the linear analogue self-assessment (LASA) questionnaire for each regimen.
III. To determine the safety of the combination of ramucirumab with TAS-102 in this patient population.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TAS-102 orally (PO) twice daily (BID) on days 1-5 and 8-12, and ramucirumab intravenously (IV) over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30-35 days, then every 3 months for up to 3 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259
- Mayo Clinic in Arizona
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224-9980
- Mayo Clinic in Florida
-
Weston, Florida, Forenede Stater, 33331
- Cleveland Clinic-Weston
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Minnesota
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Metro Minnesota Community Oncology Research Consortium
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Age >= 18 years
-
Histological or cytological confirmation of adenocarcinoma of the stomach or gastroesophageal junction
-
Have locally advanced unresectable or metastatic disease that has progressed =< 180 days since last treatment
-
One or more measurable or nonmeasurable evaluable lesions per Response Evaluation Criteria in Solid Tumors (RECIST)
-
Planned for second line treatment defined by failing or were intolerant to previous standard chemotherapies containing one or more of the following agents:
- Fluoropyrimidine (IV 5-FU or capecitabine) and platinum (cisplatin or oxaliplatin)
- Trastuzumab in case of HER2-positive disease
- NOTE: For the patients whose disease recurred =< 168 days from the last dose of adjuvant anticancer chemotherapy, that adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
-
Ability to swallow oral medications
-
Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 7 days prior to registration)
-
Platelet count >= 100,000/mm^3 (obtained =< 7 days prior to registration)
-
Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to registration)
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)
-
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN ( =< 5.0 x UNL, if with liver metastasis) (obtained =< 7 days prior to registration)
-
International normalized ratio (INR) =< 1.5 x ULN, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy) (obtained =< 7 days prior to registration)
- Note: Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy
- Note: Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH)
- Exception: If receiving warfarin, the patient must have an INR =< 3.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)
-
Urinary protein is =< 1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate =< 1000 mg of protein in 24 hours to allow participation in this protocol) (obtained =< 7 days prior to registration)
-
Creatinine =< 1.5 times the ULN or creatinine clearance (measured via 24-hour urine collection) >= 50 mL/minute (that is, if serum creatinine is >= 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) (obtained =< 7 days prior to registration)
-
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
-
Ability to complete questionnaire(s) by themselves or with assistance
-
Provide informed written consent =< 28 days prior to registration
-
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
-
Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)
Exclusion Criteria:
-
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
-
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
-
Previous treatment with TAS-102 or ramucirumab
-
Previous taxane therapy =< 180 days prior to registration
-
Any grade 3-4 gastrointestinal (GI) bleeding =< 90 days prior to registration
-
History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") =< 90 days prior to registration
-
Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, =< 180 days prior to registration
-
Prior history of GI perforation/fistula =< 180 days of registration or risk factors for perforation
-
Serious or nonhealing wound, ulcer, or bone fracture =< 28 days prior to registration
-
Major surgery =< 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement =< 7 days prior to registration
-
Elective or planned major surgery to be performed during the course of the clinical trial
-
Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. NOTE: Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
-
Uncontrolled or poorly-controlled hypertension (>= 150 mmHg systolic or >= 90 mmHg diastolic for >= 4 weeks) despite standard medical management
-
Immunocompromised and known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
- NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
-
Other active malignancy =< 3 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
-
Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. NOTE: Once-daily aspirin use (maximum dose 325 mg/day) is permitted
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm A (TAS-102, ramucirumab)
Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. |
Complete questionnaires
Andre navne:
Given IV
Andre navne:
Given PO
Andre navne:
|
|
Aktiv komparator: Arm B (paclitaxel, ramucirumab)
Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Complete questionnaires
Andre navne:
Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival
Tidsramme: 1 year
|
Progression free survival is defined as the time interval between randomization date and the date of disease progression or death (referred to as an "event"), whichever occurs first. Disease progression will be determined based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The median progression free survival will be estimated using the Kaplan-Meier method for each arm, corresponding 95% confidence intervals will be reported. |
1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: 3 years
|
Median OS will be estimated using the Kaplan-Meier method. Patients who do not experience death while on study will be censored at the last known date alive. The median OS and corresponding 95% confidence interval will be reported by arm. |
3 years
|
|
Quality of Life (QOL)
Tidsramme: Up to approximately 8 months
|
Patient reported QOL outcomes will be collected using the Linear Analog Self-Assessment (LASA) Questionnaire. Data will be collected each cycle. Mean values of the first question (regarding overall QOL) at each cycle will be plotted, and stratified by arm. Patient-reported quality of life was assessed using Question 1 of the Linear Analog Scale Assessment (LASA) of Quality of Life, which assesses overall quality of life over the past week on a scale from 0 to 10, where 0 represents the worst possible quality of life and 10 represents the best possible quality of life. Higher scores indicate better quality of life. Mean scores were calculated at each cycle and reported by treatment arm. |
Up to approximately 8 months
|
|
Incidence of Adverse Events
Tidsramme: 1 year
|
Adverse events will be recorded using Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients who experience a grade 3+ adverse event at least possibly related to treatment will be reported by arm. |
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Mohamad B Sonbol, Academic and Community Cancer Research United
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Taxoider
- Cyclodecanes
- Diterpenes
- Pyrimidin -nukleosider
- Pyrimidiner
- Sundhedsøkonomi og organisationer
- Nukleosider
- Deoxyribonucleosider
- Thymidin
- Økonomi
- Ramucirumab
- Paclitaxel
- Trifluridin
- trifluridin tipiracil lægemiddelkombination
- Skatter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ACCRU-GI-1810
- P30CA015083 (U.S. NIH-bevilling/kontrakt)
- ACCRU-GI-1810 (Anden identifikator: Academic and Community Cancer Research United)
- NCI-2020-11436 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .